All In Biotech

Drug Trial Radar · NCT02559778

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Newly Diagnosed High-Risk Neuroblastoma

Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Sep 2015

Primary completion

Sep 2030

Study completion Sep 2035

Sponsor

Lead sponsor
Giselle ShollerAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Dell, Inc.; Beat NB Cancer Foundation; K C Pharmaceuticals Inc.; Team Parker for Life
First posted
Sep 24, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Newly Diagnosed High-Risk Neuroblastoma.

Conditions

  • Neuroblastoma

Interventions

  • CeritinibDrug

    One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.

  • dasatinibDrug

    One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.

  • sorafenibDrug

    One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.

  • vorinostatDrug

    One of the following drugs will be chosen for each subject based on molecular guided results: Ceritinib, dasatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy +/- DFMO, and then all subjects will receive DFMO for 2 years as maintenance.

  • DFMODrug

    DFMO will be given to Arm B during immunotherapy and then for 2 years as maintenance to all subjects completing immunotherapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of days from start of therapy to date of first relapseTime frame: Up to 8 years
  2. Number of subjects that have a targeted agent chosen for treatment.Time frame: 2 years
  3. Number of subjects that receive 75% of dosing of medications while on study protocol during cycles 3-6.Time frame: 2 years

Locations

28 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama/Children's of Alabama

    Birmingham, Alabama · Recruiting

  • Arkansas Children's Hospital

    Little Rock, Arkansas · Recruiting

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California · Recruiting

  • Rady Children's Hospital

    San Diego, California · Recruiting

  • Connecticut Children's Hospital

    Hartford, Connecticut · Recruiting

  • Nicklaus Children's Miami

    Miami, Florida · Recruiting

  • Arnold Palmer Hospital for Children

    Orlando, Florida · Recruiting

  • St. Joseph's Children's Hospital

    Tampa, Florida · Recruiting

  • Augusta University Health

    Augusta, Georgia · Recruiting

  • Kapiolani Medical Center for Women and Children

    Honolulu, Hawaii · Recruiting

  • St. Lukes

    Boise, Idaho · Completed

  • Advocate Aurora Research Institute

    Chicago, Illinois · Completed

  • Norton Children's Research Institute/Affiliated with University of Louisville School of Medicine

    Louisville, Kentucky · Recruiting

  • Helen DeVos Children's Hospital

    Grand Rapids, Michigan · Recruiting

  • Children's Hospital and Clinics of Minnesota

    Minneapolis, Minnesota · Recruiting

  • Children's Mercy Hospitals and Clinics

    Kansas City, Missouri · Completed

  • Cardinal Glennon Children's Medical Center

    St Louis, Missouri · Recruiting

  • Hackensack University Medical Center

    Hackensack, New Jersey · Completed

  • Levine Children's Hospital

    Charlotte, North Carolina · Recruiting

  • Randall Children's Hospital

    Portland, Oregon · Recruiting

  • Penn State Milton S. Hershey Medical Center and Children's Hospital

    Hershey, Pennsylvania · Recruiting

  • Medical University of South Carolina

    Charleston, South Carolina · Recruiting

  • Dell Children's Blood and Cancer Center

    Austin, Texas · Recruiting

  • Children's Medical Center

    Dallas, Texas · Recruiting

  • Alberta Children's Hospital

    Calgary, Alberta, Canada · Recruiting

  • CHU Sainte-Justine

    Montreal, Quebec, Canada · Recruiting

  • CHUQ

    Québec, Quebec, Canada · Recruiting

  • CIUSSS de l'Estrie-CHUS

    Sherbrooke, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.